Company History

  • 2012

    Company inception

  • 2013

    Became eligible for tax incentives programs under the Act for the Development of Biotech and New Pharmaceutical Industry, Minister of Economic Affairs

  • 2014

    Turned public in compliance with regulations governed by Securities and Futures Bureau of Financial Supervisory Committee

    Stock trading on Emerging Stock Board of Taipei Exchange, stock ticker: 6499

  • 2015

    U.S. Food and Drug Administration 510(k) clearance for ClickClean™ (LAP-A01) Laparoscope Lens Shield Device

    Successful First-in-Man Studies for XPro™ (IVC-C01, now Cross-Seal™) Large Bore Suture-Mediated Vascular Closure Device

  • 2016

    Publicly listed on Taipei Exchange, stock ticker: 6499

    U.S. Food and Drug Administration 510(k) clearance for AbClose™(LAP-C01) Trocar Wound Closure Device

    Invested in Prodeon to develop the Mercury Project (URO-T01) for treatment of Benign Prostatic Hyperplasia (BPH)

    Invested in Delta Asia to enrich manufacturing capability

  • 2017

    Invested in Panther Orthopedics to develop PUMA™ System, the novel “dynamic fixation” solution to treat orthopedic extremity injuries

    Incepted the CE studies for XPro™ System (IVC-C01, now Cross-Seal™) Large Bore Suture-Mediated Vascular Closure Device

  • 2018

    Entered into an Asset Purchase Agreement with Terumo for XPro™ System (IVC-C01, now Cross-Seal™) Large Bore Suture-Mediated Vascular Closure Device

    Panther Orthopedics, Inc. Received FDA 510(k) Clearance for the PUMA™ System

    Invested in Aquedeon Medical to develop the thoracic aortic repair device

    Successful clinical use of the PUMA™ System

  • 2019

    Secondary public offering completed